The Potential — and Pitfalls — of Biosimilars

Navigant on Healthcare Podcast

With a global forecast of $30 billion by 2020, biosimilars of market-leading therapeutics are a reality. Why, then, would lower-cost medications mean lower provider profits? Here, we discuss how reimbursement is an obstacle to broad adoption.

 

Download the Full Transcript

About the Experts

Back to top